JosephEricLevittMD
Pulmonology • Stanford, CACritical Care Medicine
Assistant Professor of Medicine - Pulmonary & Critical Care Medicine, Stanford University School of Medicine
Dr. Levitt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000Fax+1 650-725-5489
Summary
- I am double board certified in pulmonary medicine and critical care medicine and have been in practice for more than 10 years. In the outpatient setting, I specialize in the treatment of adult pulmonary diseases including COPD, asthma, bronchiectasis, chronic cough, sarcoidosis, and pulmonary infections. In addition, I am a critical care intensivist with a specific research interest in the clinical management of the Acute Respiratory Distress Syndrome (ARDS).
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2005
University of ChicagoResidency, Internal Medicine, 1999 - 2001
University of Arizona College of Medicine-TucsonInternship, Internal Medicine, 1998 - 1999
University of Minnesota Medical SchoolClass of 1998
Certifications & Licensure
CA State Medical License 2004 - 2026
IL State Medical License 1999 - 2005- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- LIPS-A: Lung Injury Prevention Study With Aspirin Start of enrollment: 2012 Jan 01
- Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome Start of enrollment: 2013 Jul 01
- LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 184 citationsCytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.Jennifer G. Wilson, Laura J. Simpson, Anne-Maud Ferreira, Arjun Rustagi, Jonasel Roque
JCI Insight. 2020-09-03 - 394 citationsTreatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.Michael A. Matthay, Carolyn S. Calfee, Hanjing Zhuo, B. Taylor Thompson, Jennifer G. Wilson
The Lancet. Respiratory Medicine. 2019-02-01 - 536 citationsMesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trialJennifer G. Wilson, Kathleen D. Liu, Hanjing Zhuo, Lizette Caballero, Melanie McMillan
The Lancet. Respiratory Medicine. 2015-01-01
Press Mentions
Covid-19: Know Thy Enemy and Divine the SignMay 30th, 2020
How Does Coronavirus Kill? Clinicians Trace a Ferocious Rampage Through the Body, from Brain to ToesApril 17th, 2020
Grant Support
- Early Acute Lung Injury: Prospective Evaluation Prior To Respiratory FailureNational Heart, Lung, And Blood Institute2009–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
